No abstract

Aim and Objectives The purpose of this work was to demonstrate the economic advantage of a generic lenalidomide in real practice, showing and comparing costs and consumption during the period 2021 to 2022. Material and Methods To conduct this analysis, patients, type of prescription (originator or generic), number of patients treated, number of cycles, administered milligrams and purchase prices, during the period September 2021 to August 2022, were extrapolated from pharmacy software and matched.Results Compared with period from September 2021 to February 2022, during March to August2022, the number of treated patients remained similar (105 vs 104) and the number of cycles administered (388 vs 390).

No abstract

No abstract

No abstract